Market Cap 13.31B
Revenue (ttm) 8.33B
Net Income (ttm) 1.56B
EPS (ttm) N/A
PE Ratio 12.30
Forward PE 11.69
Profit Margin 18.69%
Debt to Equity Ratio 1.02
Volume 1,629,300
Avg Vol 1,453,636
Day's Range N/A - N/A
Shares Out 173.18M
Stochastic %K 86%
Beta 0.59
Analysts Sell
Price Target $81.38

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temp...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Address:
1750 Yankee Doodle Road, Eagan, United States
HarrietteBall
HarrietteBall May. 24 at 3:53 AM
$CVKD https://www.globenewswire.com/news-release/2026/05/07/3290023/0/en/cadrenal-therapeutics-reports-first-quarter-2026-financial-results-and-provides-phase-3-development-update-on-cad-1005-following-end-of-phase-2-meeting-with-fda.html Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-reports-first-quarter-2026-financial-results-3c9fl7b7u4xe.html $SOLV $JOBY $AMZN
0 · Reply
OnlyFibs
OnlyFibs May. 23 at 6:38 PM
$SOLV is reclaiming critical structural resistance on high volume. 🏥 The post-spin-off volatility is settling, and the institutional accumulation is undeniable. Solventum is leaning into its high-growth med-tech segments, and the market is finally rewarding the standalone strategy. With the technical trend flipping, this looks like the start of a meaningful move. 🎯 🐂 Bulls: Need to hold 72.00 as a floor to force a weekly close over 78.00 targeting 85.00+ 🐻 Bears: Need to crack 68.00 to stall the momentum and slide back to 60.00 📊 Lean BULLISH. #SOLV #MedTech #Investing #hovdid
0 · Reply
SmashDipRoll
SmashDipRoll May. 22 at 5:06 PM
$INGM $SOLV $PTRN Holding these for mid to long term swing.
0 · Reply
TheArtOfFinancialWar
TheArtOfFinancialWar May. 19 at 1:42 PM
$SOLV this stock is included in Notorious Nine 2029. I ran out of space in my bio so I’ll condense everything 😆 @LetsGoMets10 so far $VGNT $VSNT and SOLV made the list after Shao Yong hexagrams and asking Caodaist and Taoist friends regarding their planchette writing results. @TaoistTrader @mhparvez goal is to beat $SPY as usual
0 · Reply
Robb88
Robb88 May. 12 at 6:14 AM
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 3:20 AM
$SOLV Price: $74.12 (+1.01%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.48% RSI: 67.9 | Momentum: Moderate Volume: +15.2% vs avg Volatility: 1.65% Support: $65.44 | Resistance: $74.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
OpenOutcrier
OpenOutcrier May. 6 at 12:32 PM
$SOLV (-2.8% pre) Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations https://ooc.bz/l/101261
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:15 PM
$SOLV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 down -91.14% YoY • Reported revenue of $2.01B down -3.04% YoY • Solventum affirmed full-year 2026 organic sales growth guidance of +2.0% to +3.0% and estimates adjusted diluted EPS will be toward the high end of the $6.40 to $6.60 range.
0 · Reply
bigbulldaddy
bigbulldaddy May. 2 at 3:13 PM
$SOLV https://www.globenewswire.com/news-release/2026/04/30/3285301/0/en/trian-calls-on-solventum-s-board-to-create-value-publishes-open-letter-and-slide-deck.html Have to agree with a lot of this view point. HIS could become valuable or get completely replaced by newer AI programs. Harder to sell for max value now in the current software environment but I would say that risk only increases from here with time. We laid off an entire role and are forcing reps to do as much as 2x the work with no additional pay. Many reps have one foot in and one foot out of the company. Restrata/Ascera will bring value but slower than anticipated at the value we paid for it. They seem content to hold their employees down while desperately looking for funds to buy more companies. That doesn’t seem like a solid long term strategy. People are in roles they weren’t ready for. Training is inadequate. Moral amongst employees is breaking and there isn’t a fast enough plan to fix it. Stock is flat
0 · Reply
LongLTC
LongLTC May. 1 at 2:47 AM
$SOLV Hard to believe the market has missed this gem! I am accumulating at these levels!
0 · Reply
Latest News on SOLV
Wedbush bullish on Solventum, initiates with an Outperform

2026-05-15T13:49:50.000Z - 8 days ago

Wedbush bullish on Solventum, initiates with an Outperform

MMM


Solventum Transcript: AGM 2026

May 15, 2026, 9:00 AM EDT - 8 days ago

Solventum Transcript: AGM 2026


Solventum initiated with an Outperform at Wedbush

2026-05-15T12:02:51.000Z - 8 days ago

Solventum initiated with an Outperform at Wedbush


Solventum price target raised to $93 from $92 at KeyBanc

2026-05-07T09:40:49.000Z - 17 days ago

Solventum price target raised to $93 from $92 at KeyBanc


Solventum price target lowered to $90 from $105 at Stifel

2026-05-07T07:56:39.000Z - 17 days ago

Solventum price target lowered to $90 from $105 at Stifel


Solventum price target lowered to $78 from $82 at UBS

2026-05-07T04:10:03.000Z - 17 days ago

Solventum price target lowered to $78 from $82 at UBS


Solventum Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 18 days ago

Solventum Earnings Call Transcript: Q1 2026


Solventum Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 18 days ago

Solventum Earnings release: Q1 2026


Solventum Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 18 days ago

Solventum Slides: Q1 2026


Solventum Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 18 days ago

Solventum Quarterly report: Q1 2026


Solventum Shareholder letter: Q1 2026

May 5, 2026, 4:30 PM EDT - 18 days ago

Solventum Shareholder letter: Q1 2026


Solventum Reports First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 18 days ago

Solventum Reports First Quarter 2026 Financial Results


Trian calls on Solventum board to ‘drive value creation’

2026-04-30T17:33:31.000Z - 23 days ago

Trian calls on Solventum board to ‘drive value creation’


Solventum price target lowered to $92 from $99 at KeyBanc

2026-04-27T10:25:28.000Z - 26 days ago

Solventum price target lowered to $92 from $99 at KeyBanc


Solventum price target lowered to $89 from $100 at BTIG

2026-04-13T12:11:23.000Z - 5 weeks ago

Solventum price target lowered to $89 from $100 at BTIG


Solventum Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Solventum Proxy statement: Proxy filing


Solventum Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Solventum Proxy statement: Proxy filing


Solventum initiated with a Sell at Rothschild & Co Redburn

2026-03-24T09:06:00.000Z - 2 months ago

Solventum initiated with a Sell at Rothschild & Co Redburn


Solventum assumed with an Equal Weight at Wells Fargo

2026-03-18T10:25:12.000Z - 2 months ago

Solventum assumed with an Equal Weight at Wells Fargo


Solventum to Participate in the 2026 KeyBanc Healthcare Forum

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Solventum to Participate in the 2026 KeyBanc Healthcare Forum


Solventum price target raised to $82 from $79 at UBS

2026-03-02T14:13:59.000Z - 2 months ago

Solventum price target raised to $82 from $79 at UBS


Solventum price target raised to $99 from $97 at KeyBanc

2026-02-27T13:19:06.000Z - 3 months ago

Solventum price target raised to $99 from $97 at KeyBanc


Solventum Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Solventum Earnings Call Transcript: Q4 2025


Solventum Shareholder letter: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Solventum Shareholder letter: Q4 2025


Solventum Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Solventum Annual report: Q4 2025


Solventum Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Solventum Earnings release: Q4 2025


Solventum Slides: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Solventum Slides: Q4 2025


Solventum sees 2026 adjusted EPS $6.40-$6.60, consensus $6.34

2026-02-26T21:27:47.000Z - 3 months ago

Solventum sees 2026 adjusted EPS $6.40-$6.60, consensus $6.34


Solventum reports Q4 adjusted EPS $1.57, consensus $1.50

2026-02-26T21:10:20.000Z - 3 months ago

Solventum reports Q4 adjusted EPS $1.57, consensus $1.50


Solventum upgraded to Overweight from Sector Weight at KeyBanc

2026-01-26T09:50:08.000Z - 4 months ago

Solventum upgraded to Overweight from Sector Weight at KeyBanc


Solventum Completes Acquisition of Acera Surgical

Dec 23, 2025, 4:05 PM EST - 5 months ago

Solventum Completes Acquisition of Acera Surgical


Solventum Announces $1 Billion Share Repurchase Program

Nov 20, 2025, 9:00 AM EST - 6 months ago

Solventum Announces $1 Billion Share Repurchase Program


Solventum Announces Agreement to Acquire Acera Surgical

Nov 20, 2025, 9:00 AM EST - 6 months ago

Solventum Announces Agreement to Acquire Acera Surgical


Solventum Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 11:20 AM EST - 6 months ago

Solventum Transcript: Stifel 2025 Healthcare Conference


Solventum Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Solventum Earnings Call Transcript: Q3 2025


Solventum Shareholder letter: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Solventum Shareholder letter: Q3 2025


Solventum Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Solventum Quarterly report: Q3 2025


Solventum Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Solventum Earnings release: Q3 2025


Solventum Slides: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Solventum Slides: Q3 2025


Solventum Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

Solventum Reports Third Quarter 2025 Financial Results


Solventum Appoints Heather Knight as Chief Commercial Officer

Oct 21, 2025, 5:00 PM EDT - 7 months ago

Solventum Appoints Heather Knight as Chief Commercial Officer


Solventum to Participate in Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 9 months ago

Solventum to Participate in Upcoming Investor Conferences


Solventum Announces $1.75 Billion Note Tender Offers

Aug 22, 2025, 8:19 AM EDT - 9 months ago

Solventum Announces $1.75 Billion Note Tender Offers


Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 10:39 PM EDT - 10 months ago

Solventum Announces Pricing of Secondary Offering of Common Stock


Solventum Announces Launch of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 10 months ago

Solventum Announces Launch of Secondary Offering of Common Stock


Solventum Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Solventum Earnings Call Transcript: Q2 2025


Solventum Shareholder letter: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Solventum Shareholder letter: Q2 2025


Solventum Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Solventum Quarterly report: Q2 2025


Solventum Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Solventum Earnings release: Q2 2025


Solventum Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Solventum Slides: Q2 2025


Solventum Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 10 months ago

Solventum Reports Second Quarter 2025 Financial Results


Solventum Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Solventum Earnings Call Transcript: Q1 2025


Solventum Shareholder letter: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Solventum Shareholder letter: Q1 2025


Solventum Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Solventum Quarterly report: Q1 2025


Solventum Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Solventum Earnings release: Q1 2025


Solventum Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Solventum Slides: Q1 2025


Solventum Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Solventum Reports First Quarter 2025 Financial Results


Solventum Proxy statement: Proxy Filing

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Solventum Proxy statement: Proxy Filing


Solventum Proxy statement: Proxy Filing

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Solventum Proxy statement: Proxy Filing


Solventum Transcript: Investor Day 2025

Mar 20, 2025, 1:00 PM EDT - 1 year ago

Solventum Transcript: Investor Day 2025


Solventum Slides: FY 2025

Mar 20, 2025, 1:00 PM EDT - 1 year ago

Solventum Slides: FY 2025


Solventum Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Solventum Earnings Call Transcript: Q4 2024


Solventum Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Solventum Annual report: Q4 2024


Solventum Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Solventum Earnings release: Q4 2024


Solventum Slides: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Solventum Slides: Q4 2024


HarrietteBall
HarrietteBall May. 24 at 3:53 AM
$CVKD https://www.globenewswire.com/news-release/2026/05/07/3290023/0/en/cadrenal-therapeutics-reports-first-quarter-2026-financial-results-and-provides-phase-3-development-update-on-cad-1005-following-end-of-phase-2-meeting-with-fda.html Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-reports-first-quarter-2026-financial-results-3c9fl7b7u4xe.html $SOLV $JOBY $AMZN
0 · Reply
OnlyFibs
OnlyFibs May. 23 at 6:38 PM
$SOLV is reclaiming critical structural resistance on high volume. 🏥 The post-spin-off volatility is settling, and the institutional accumulation is undeniable. Solventum is leaning into its high-growth med-tech segments, and the market is finally rewarding the standalone strategy. With the technical trend flipping, this looks like the start of a meaningful move. 🎯 🐂 Bulls: Need to hold 72.00 as a floor to force a weekly close over 78.00 targeting 85.00+ 🐻 Bears: Need to crack 68.00 to stall the momentum and slide back to 60.00 📊 Lean BULLISH. #SOLV #MedTech #Investing #hovdid
0 · Reply
SmashDipRoll
SmashDipRoll May. 22 at 5:06 PM
$INGM $SOLV $PTRN Holding these for mid to long term swing.
0 · Reply
TheArtOfFinancialWar
TheArtOfFinancialWar May. 19 at 1:42 PM
$SOLV this stock is included in Notorious Nine 2029. I ran out of space in my bio so I’ll condense everything 😆 @LetsGoMets10 so far $VGNT $VSNT and SOLV made the list after Shao Yong hexagrams and asking Caodaist and Taoist friends regarding their planchette writing results. @TaoistTrader @mhparvez goal is to beat $SPY as usual
0 · Reply
Robb88
Robb88 May. 12 at 6:14 AM
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 3:20 AM
$SOLV Price: $74.12 (+1.01%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.48% RSI: 67.9 | Momentum: Moderate Volume: +15.2% vs avg Volatility: 1.65% Support: $65.44 | Resistance: $74.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
OpenOutcrier
OpenOutcrier May. 6 at 12:32 PM
$SOLV (-2.8% pre) Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations https://ooc.bz/l/101261
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 8:15 PM
$SOLV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 down -91.14% YoY • Reported revenue of $2.01B down -3.04% YoY • Solventum affirmed full-year 2026 organic sales growth guidance of +2.0% to +3.0% and estimates adjusted diluted EPS will be toward the high end of the $6.40 to $6.60 range.
0 · Reply
bigbulldaddy
bigbulldaddy May. 2 at 3:13 PM
$SOLV https://www.globenewswire.com/news-release/2026/04/30/3285301/0/en/trian-calls-on-solventum-s-board-to-create-value-publishes-open-letter-and-slide-deck.html Have to agree with a lot of this view point. HIS could become valuable or get completely replaced by newer AI programs. Harder to sell for max value now in the current software environment but I would say that risk only increases from here with time. We laid off an entire role and are forcing reps to do as much as 2x the work with no additional pay. Many reps have one foot in and one foot out of the company. Restrata/Ascera will bring value but slower than anticipated at the value we paid for it. They seem content to hold their employees down while desperately looking for funds to buy more companies. That doesn’t seem like a solid long term strategy. People are in roles they weren’t ready for. Training is inadequate. Moral amongst employees is breaking and there isn’t a fast enough plan to fix it. Stock is flat
0 · Reply
LongLTC
LongLTC May. 1 at 2:47 AM
$SOLV Hard to believe the market has missed this gem! I am accumulating at these levels!
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 30 at 8:00 PM
RECAP 4/30 Chatter: $AXSM + Auvelity approved $SOLV + Trian $SKBL + Trump Sons Stake Live Breaking trading news www.openoutcrier.com
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 7:41 PM
$SOLV Share Price: $67.34 Contract Selected: Oct 16, 2026 $65 Calls Buy Zone: $5.78 – $7.14 Target Zone: $9.59 – $11.72 Potential Upside: 57% ROI Time to Expiration: 168 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Robb88
Robb88 Apr. 29 at 3:10 AM
$EIGEN.X dont sleep on this and $SOLV
1 · Reply
luckymox
luckymox Mar. 23 at 6:19 PM
$SOLV should be some decent support in this range
0 · Reply
Boston7452
Boston7452 Mar. 21 at 5:31 PM
$SOLV best chance for significant revenue growth, i believe, will come for its Medsurg division. All it needs to do is bring new mask products, PPE, air filtration, and woundcare products with Anti-viral/Anti-bacteria capabilities to market before the next pandemic. Current estimates for the next pandemic is late 2027 / early 2028. Pandemic maybe 1 or more respiratory viruses circulating at the same time like we saw this winter with so many schools shutting down due to amount of teachers/students out sick.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 11:02 PM
$SOLV RSI: 28.05, MACD: -2.3810 Vol: 3.56, MA20: 73.58, MA50: 77.28 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
Estimize
Estimize Mar. 9 at 12:00 PM
Wall St is expecting 1.35 EPS for $SOLV Q1 [Reporting 05/07 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co
0 · Reply
bigbulldaddy
bigbulldaddy Mar. 2 at 2:41 PM
$SOLV Restrata integration appears slower than anticipated. Company also has a huge risk in HIS business over next 3-5 years with other SAAS AI plays ramping up. Could result in a large portion of the SOLV business/revenue breaking down. Company appears to be making AI plays itself with help from google/amazon. Obsolescence risks identified as chat bots and LLMs become comoditized.
0 · Reply
ZacksResearch
ZacksResearch Feb. 27 at 7:44 PM
$SOLV beats Q4 estimates, but shares dip 2.5% post-earnings. Why? 🤔 🔍 EPS of $1.57 topped estimates by 4.7%, marking an 11.3% year over year improvement 📈 Revenue climbed 3.7% reportedly with strong MedSurg & Dental Solutions driving organic growth See the full analysis here 👉 https://www.zacks.com/stock/news/2877011/solventum-stock-down-despite-q4-earnings-revenues-beat-margins-down?cid=sm-stocktwits-2-2877011-body-35653&ADID=SYND_STOCKTWITS_TWEET_2_2877011_BODY_35653
0 · Reply
ZacksResearch
ZacksResearch Feb. 27 at 6:44 PM
$SOLV beats… and still gets sold. ⚠️ Q4 earnings and revenues topped estimates, powered by organic growth across MedSurg, Dental and HIS — but margins declined, and that’s what the market is zeroing in on. Growth is there, but margin pressure is the swing factor. See the full breakdown here 👉 https://www.zacks.com/stock/news/2877011/solventum-stock-down-despite-q4-earnings-revenues-beat-margins-down?cid=sm-stocktwits-2-2877011-teaser-35635&ADID=SYND_STOCKTWITS_TWEET_2_2877011_TEASER_35635
0 · Reply